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Abstract:  
Although  nowadays  performed  on  a  routine  basis,  catheter  ablation  of  atrial  fibrillation  is 
associated with the potential for major complications. Improving the safety remains therefore 
an important challenge. This article summarizes the different types of complications associated 
with AF ablation grouping them into clinically overt major complications, subclinical injury 
and permanent injury. Furthermore, it describes the potential predictors for complications and 
highlights the dynamic interplay between efficacy and safety. 
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Major complications and sequellae after ablation of AF                                      
Percutaneous catheter ablation is a well-established, efficient and effective treatment strategy 
for recurrent, symptomatic and drug-resistant atrial  fibrillation (AF).[1] Major complications 
though occur in up to 5.9% of procedures (Table 1).[2-13] Taking into account the relatively 
benign nature of AF, this complication rate is a major point of concern. Besides the clinically 
overt  major  complications,  one  should  also  consider  other  sequellae,  like  ablation-induced 
subclinical  events  and  permanent  injury.                                        
Clinically  overt  major  complications                                          
From  its  early  phase  on,  catheter  ablation  of  AF  is  linked  to  potentially  devastating 
complications as stroke, cardiac tamponade, atrio-esophageal fistula and pulmonary vein (PV) 
stenosis. Furthermore death might occur in up to 1 out of 1000 patients.[14] Table 1 lists up the 
prevalence of clinically  overt  major complicationsas observed in large single-centre studies, 
multi-centre  trials,  and  the  world-wide  surveys.[2-13]  In  general,  a  major  complication  - 
defined  as  any  procedure  related  adverseevent  requiring  intervention,  causing  long-term 
disability or death or resulting in prolongation of hospital stay - occurs in 0.8 to 5.9% (median 
4%) of  procedures.  Although  the  relative  distribution  of  specific  types  of  complications  is 
different between the reports, in general there are three major "1%" complications: stroke or 
TIA, tamponade and major vascular injury. A wide variety of other complications accounts for 
the remaining 1% (Table 1).  Interestingly,  overall  major  complication  rate  does  not  differ 
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between older and more recent reports (from the left to the right side of the table). This finding 
is paralleled by the similar complications rates reported in the first and second survey.[2,10]
Table  1. Major  AF  ablation  reports  (ranked  in  chronological  order,  from  2005  to  2011) 
addressing safety. See text for further explanation. N=Number, TIA=Transient Ischemic Attack.
Subclinical  events                                     
Because of the silent nature of certain events, overall complication rate of AF ablation (as listed 
in  Table 1) is likely to be underestimated. It is well-recognised that the prevalence of events 
like deep venous thrombosis, pulmonary embolism, arterio-venous fistula and  PV narrowing is 
dependent  on  the  scrutiny  of  detection.  Only  recently  it  was  recognized  that  an  overt 
thromboembolic event (stroke or TIA) most likely represents only a small part of the wider 
spectrum  of  cardio-embolic  events.  MRI  studies  of  the  brain  demonstrated  asymptomatic 
cerebral  emboli  (ACE)  in  a  substantial  number  (14%)  of  patients  after  AF  ablation.[15] 
Although none of the most widely-used ablation strategies seems immune to ACE, there is a 
variability in the incidence: use of the PVAC catheter was associated with a significantly higher 
rate of ACE (37.5%) in comparison to irrigated-RF (7.4%) or cryoballoon energy (4.3%).[16] 
Several questions regarding ACE (its clinical significance?, exact nature of the lesions seen on 
MRI?, reversibility?)  remain unanswered and prevent us to draw more definite conclusions.
Also ablation-induced PV narrowing is an event likely to remain largely undetecteddue to its 
silent  nature and inconsistent  follow-up. Our group recently reported the impact  of PVAC-
ablation on PV diameters.[17] Moderate PV narrowing (i.e. diameter reduction 25% to 50%) 
and severe PV narrowing (i.e. diameter reduction >50%) occurred in respectively 28% and 4% 
of  PVs.[17]  Only  1  out  of  50  patients  showing  moderate  to  severe  PV  narrowing  was 
symptomatic. In comparison, after point-by-point circumferential PV-antrum isolation, severe 
PV narrowing (>50%) occurred in 3.8% of PVs.[18]
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Permanent  injury                                       
Major complications after AF ablation only rarely lead to permanent injury. Hoyt el al. reported 
an overall major complication rate of 4.7% but permanent deficit was observed in only 0.5% of 
patients.[19] Likewise, Dagres et al., reporting safety of AF ablation in 1000 procedures, stated 
that  the  vast  majority  of  encountered  major  complications  could  be  treated  conservatively 
without permanent residues.[8] On the other hand, permanent injury might remain undetected. 
Schwartz  et  al.  noted  that  ablated  patients  showed a worse neuropsychological  outcome in 
verbal memory in comparison to baseline and control non-AF patients.[20] Although these data 
differ from those reported by Bunch et al.[21], it is tempting to speculate that ACE play a role 
in the decline of cognitive functioning. Also PV narrowing might lead to permanent sequellae. 
Although Arentz et al,  in 11 patients with initial  PV narrowing (>70% diameter reduction), 
observed no progression of PV stenosis at long-term follow-up (>2 years), about 63% of these 
patients  developed  pulmonary  hypertension  during  exercise.[22]  Finally,  AF  ablation  is 
associated with a marked radiation exposure to the patient.[23,24] Delayed effects of radiation 
(cancer, genetic abnormalities) are therefore another potential cause for  permanent injury. In 
fact, Lickfett et al. reported an additional lifetime risk for a fatal malignancy associated with AF 
ablation of 0.15% for female patients and 0.21% for male patients.[24,25]                   
Predictors of Complications: "Efficacy and Safety go hand in hand"                          
To reduce and potentially avoid the overall complication rate in AF ablation, it is essential to 
acknowledge the predictors of complications and the dynamic interplay between efficacy and 
safety  (Figure  1).  Like  in  most  medical  procedures,  center  and  patient  profile  act  as  key 
predictors of procedural complications. Interestingly, center and patient profile also determine 
the efficacy of AF ablation and the subsequent need for repeat ablation (dashed lines). Efficacy 
itself  is  the  3rd  predictor  of  complications,  because  patients  have  to  undergo  the  risk  of 
procedural complications for a second time during a repeat procedure (cumulative complication 
rate).
Figure 1.  There  a three  major  predictors  of  complications in  AF ablation. Center  profile  refers  to procedure 
volume, operator experience and interaction between nurses, fellows, anesthesiologists and electrophysiologists.  
The patient  profile  is  another  important  predictor  for  complications with a  higher  reported procedural  risk in 
certain subgroups (high CHADS2, female gender, older age, impaired left ventricular function). Finally, efficacy 
itself is a critical predictor for complications ("cumulative complication rate"): if efficacy is low and the patient  
needs to undergo a repeat  ablation then the patient  is exposed again to the same procedural  risk ("safety and 
efficacy go hand in hand"). Interestingly efficacy itself is determined by center and patient profile (dashed lines).    
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Center  profile                                                   
It is well established that institutional experience and center volume have an impact on efficacy 
of AF ablation (Figure 1, dashed line).[2] More recently, center profile was found to be linked 
with  safety  as  well  (Figure  1,  solid  line).  In  the  study  by  Hoyt  et  al.,  studying  major 
complication rate over time, a significant decrease was noted from 11.1% in 2002 to1.6% in 
2010 while  the annual  procedure volume and the number of AF ablationists  increased.[19] 
Interestingly, center profile has a greater impact on overall procedural safety than the individual 
experience of the operator. In the study of Dagres et al. no relationship was found between the 
operator  and  the  complication  rate  with  a  very  experienced  operator  having  the  highest 
complication rate.[8] Hoyt et al found  no statistical difference in complication rate between 
junior faculty (performing<30 AF ablations) and the senior faculty (>30 ablations).[19] Most 
likely, choices to change practice pattern over time have a major influence on complication rate. 
For instance,  after  the introduction  of an esophageal  temperature  probe no A-E fistula  was 
observed in the Leipzig experience.[8] Also changes in ablation strategy (wide circumferential 
PV isolation instead of segmental PV isolation), use of irrigated catheters or adoption of new 
peri-procedural  anticoagulation  regimens  reflect  center  rather  than  operator  profile.        
Patient  profile                                                   
In young paroxysmal  AF patients  without  structural  heart  disease and no LA enlargement, 
reported procedural risk can be as low as 0.8%.[12] Other studies, reporting ablation outcome 
in  a  more  heterogeneous  patient  population,  have  identified  subgroups  at  higher  risk  for 
complications:  (1)  a  higher  CHADS2 score,  (2)  female  gender,  (3)  older  age  and  (4)  the 
presence of heart failure. Chao et al. observed that the overall procedural complication rate was 
greater in patients with a higher CHADS2 score.[26,27] Similarly a CHADS2 score of ≥2 has 
previously been recognised as an independent predictor of peri-procedural stroke,[28] whereas 
other studies reported absence of stroke in CHADS2 0 or 1 patients.[29] Patel et al. reported 
that female patients had more major complications (5%) compared to male patients (2.4%).[30] 
A higher procedural risk in women was also observed in other cardiovascular interventions like 
percutaneous coronary intervention.[31] Zado et al. compared AF ablation between age groups 
(<65yrs,  65-74y,  ≥75y)  and  found  a  trend  towards  more  complications  in  the  elderly.[32] 
Likewise, Spragg et al reported a nearly 4-fold increase (in comparison to younger patients) in 
major complication rate over the age of 70.[6] Finally, Chen et al compared AF ablation in 
patients  with  normal  and  impaired  systolic  function.[33]  In  comparison  to  patients  with  a 
normal systolic function, major complication rate was higher in patients with impaired systolic 
function  (4.3%  vs  3.5%).                                                
Interestingly, the above mentioned risk factors for complications - i.e. higher CHADS2 score, 
female gender, older age (≥75yrs) and low ejection fraction -also determine the efficacy of the 
procedure ("efficacy and safety go hand in hand"). Outcome data from those studies reporting 
both efficacy and safety within different subgroups are plotted in Figure 2. Clearly, there is a 
linear  relation  between  efficacy  and  safety  within  subgroups  of  each  study  (avoiding 
confounding variables like follow-up, center profile, ablation strategy etc) but also within all 
reported studies (dashed line). This high correlation implies that in patients at risk for a higher 
complication rate, also efficacy is expected to be lower ("efficacy and safety go hand in hand").
Efficacy  and  cumulative  complication  rate                                         
Efficacy-dependent complications are those complications related to a repeat ablation (Figure 
1). The patient is again subjected to all reported complications leading to a higher "cumulative 
complication"  rate.  Although procedure  time  and number  of  lesions  during  repeat  ablation 
might be limited, some complications might be more frequent compared to the first procedure 
e.g. due to hampered groin or transseptal access.[7] The concept of "cumulative complication 
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rate" has several  implications:  (1) Complication rate in AF ablation should be reported per 
patient rather than per procedure. Cumulative complication rate per patient should be used to 
weigh the risks and benefits of a planned procedure. (2) In patients with an expected higher 
initial complication rate (due to patient profile), the cumulative complication rate is expected to 
be even much higher due to the inherent lower efficacy and higher need for a repeat procedure 
('efficacy  and  safety  go  hand  in  hand').                                         
Figure 2. The reported risk factors (patient profile) for complications - i.e. higher CHADS2 score, female gender, 
older age (≥75years) and low ejection fraction -also determine the efficacy of the procedure ("efficacy and safety 
go hand in hand"). See text for explanation. Safety is defined as the absence of reported major complications. 
Efficacy is defined as freedom of AF after the first procedure with or without antiarrhythmic drugs. Red dots = 
study by Chao et al in subgroups with different CHADS2-scores; blue dots = study by Patel et al, in male and 
female subgroups; yellow dots = study by Zado et al comparing different age groups; green dots = study by Chen 
et  al  in  patients  with  a  preserved  and  low  ejection  fraction.                                    
How  to  avoid  Complications  in  AF  Ablation?                                  
Novel  technology                                          
It  might  be  a  realistic  goal  to  make  AF  ablation  as  effective  and  safe  as  other  cardiac 
procedures,  such as  percutaneous  coronary  interventions  or  other  ablation  procedures.  In  a 
continuous quest for a more effective, faster  and safer ablation approach, alternative forms of 
energy (ultrasound, cryo-energy, laser, microwave, etc.) and several new ablation catheters (e.g. 
magnetic catheters, "single-shot" devices as the cryoballoon and multi-electrode catheters) have 
been studied. However, it is unlikely that changes in AF ablation technology will completely 
eliminate procedure-related complications. Even in experienced hands, this technique carries a 
risk of embolic events (thrombus, air), cardiac tamponade and groin complications, all of them 
to  some  extent  related  to  the  invasive  nature  of  the  procedure  (sheaths,  guidewires, 
manipulation,  electrical  cardioversions)  and  its  peri-operative  changes  in  anticoagulation.
Benefit-risk  ratio                                         
Therefore it will remain essential to determine a tailored benefit/risk ratio in each individual 
patient referred for AF ablation. Indications for AF ablation should be based both upon safety 
and efficacy for each patient profile (Figure 3). In young patients with paroxysmal, lone AF 
(inner circle, green, left panel), efficacy and safety of AF ablation were shown to be high in 
randomised controlled trials, resulting in a high benefit to risk ratio  and a  Class I  indication 
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(right  panel).  In  older  patients,  persistent  AF,  moderate  LA  enlargement  (<50mm)  and/or 
moderate structural heart disease, often undergoing AF ablation in world-wide practice (orange 
circle,  left  panel),  large  single-centre  studies  have shown that  efficacy,  safety and thus the 
benefit to risk ratio are expected to be moderate (Class IIA indication, right panel). The outer 
circle  (red)  represents  patients  with  advanced  structural  remodelling:  octogenarians, 
longstanding persistent AF, advanced LA enlargement (>50mm) and advanced structural heart 
disease (like CHADS 3 or more, severe valvular heart disease, severely impaired EF). Several 
small  studies  have  shown  that  efficacy,  safety  and  thus  benefit  to  risk  ratio  are  low 
corresponding to a Class IIB indication, right panel). This would imply a high threshold (for 
both symptoms and number of failed drugs) before opting for AF ablation in these patients.
Figure 3. Indications (with level of recommendation) for AF ablation based upon safety and efficacy. See text for 
explanation.  LA=Left  Atrium,  SHD=  Structural  Heart  Disease,  yrs=years,  B/R=Benefit/Risk  ratio.      
Maximising  the  first  pass  efficacy                                    
Although operator/institutional experience and patient selection might be the crucial ways to 
reduce  inherent  procedural-related  complications,  maximising  the  first  pass  efficacy  rate  is 
another necessary step to avoid complications and permanent sequelae in AF ablation. Given an 
ablation strategy with a 4% complication rate, reducing the redo rate from 40% to 10% would 
decrease the cumulative complication rate from 5.6% to 4.4% (21% relative risk reduction). 
Given  the  "AF  recurrence  equals  pulmonary  vein  reconnection"  paradigm,  any  method  to 
improve permanent pulmonary vein isolation will decrease the number of repeat procedures and 
as  such  its  cumulative  complication  rate  ("efficacy  and  safety  go  hand  in  hand").      
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